Source link : https://newshealth.biz/health-news/celmod-drug-cuts-risk-of-myeloma-progression-death-by-52-in-trial/
CHICAGO — Adding a novel cereblon E3 ligase modulation (CELMoD) drug to a standard multiple myeloma regimen significantly improved progression-free survival (PFS) in a vulnerable population of patients with relapsed or refractory disease, a phase III trial showed. In participants largely refractory to lenalidomide (Revlimid) and an anti-CD38 antibody, median PFS reached 18 months with […]
The post CELMoD Drug Cuts Risk of Myeloma Progression, Death by 52% in Trial first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-01 19:10:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8